

# SOS-2016 Science of Stability

25-27th September 2016,  
Newark, NJ, USA

## The Science of Stability Conference

where “it’s all about the science”

[www.stabilityconference.com](http://www.stabilityconference.com)

Renaissance Newark  
International Airport Hotel  
Elizabeth, New Jersey, USA

Contact:  
[isamir.martinez@freethinktech.com](mailto:isamir.martinez@freethinktech.com)

**S**helf-life is a critical factor in developing and commercializing pharmaceuticals, generics, nutraceuticals, OTCs and consumer products. Since the stability of products affects their safety and efficacy, it is crucial to understand how such factors as time, temperature, humidity, oxygen and light impact their shelf-life and what tools can be applied to mitigate any issues.

*Join us in New Jersey this fall to learn about new findings from leading scientists in the field who will be sharing the latest discoveries and innovations in the science involved in stability across different industries.*

The conference will cover a range of topics including:

- The Science of Accelerated Stability Assessment Program (ASAP)
- The Use of ASAP in Product Development, including Regulatory Submissions
- Stability of Amorphous Drug Forms
- Drug Degradation Chemistry
- Moisture and its Impact on Stability Physical Stability

### WHY ATTEND the SOS 2016?

Learn to minimize time to clinic/ market  
Avoid costly surprise stability findings  
Rationally address stability issues



# *2016 SOS Program at-a-glance*

## **ASAP<sup>prime</sup>® 5.0: INTRODUCTION TO LATEST VERSION RELEASE**

### **ASAP FOR NON-TRADITIONAL FACTORS: DISSOLUTION, DISINTEGRATION & COLOR IN-USE AND EXCURSIONS: STABILITY BEYOND ICH**

Dr. Ken Waterman, FreeThink Technologies, Branford, CT, USA

## **ASAP CASE STUDY & SOLUTION-PHASE STABILITY**

Dr. Garry Scrivens, Pfizer, Sandwich, UK

## **ASAP CASE STUDY: PEPTIDE STABILITY**

Dr. Alissa Waterman, FreeThink Technologies, Branford, CT, USA

## **ASAP THEORY AND FUNDAMENTALS**

Dr. Sabine Thielges, Novartis, Basel, Switzerland

## **INTEGRATION OF ASAP IN EARLY DRUG DEVELOPMENT USING THE FAST APPROACH**

Dr. Chandan Bhugra, Boehringer Ingelheim, Ridgefield, CT, USA

## **THE USE OF ASAP FROM EARLY TO LATE DRUG DEVELOPMENT**

Dr. Eduard Luss, Vertex Pharmaceuticals, Boston, MA, USA

## **ASAP REGULATORY STRATEGY, ACCEPTANCE AND FEEDBACK**

Dr. Elke Debbie, Janssen Pharmaceuticals (J&J), Beerse, Belgium

## **ASAP APPLICATIONS IN GENERIC PRODUCTS**

Dr. Bryan Wicks, Boehringer Ingelheim, OH, USA

## **TEACHING OLD DRUGS NEW TRICKS: APPLICATIONS OF ASAP IN OTC PRODUCT DEVELOPMENT**

Dr. Jonathan E. Clark, Procter & Gamble, Cincinnati, Ohio, USA

## **MODELING THE PHYSICAL STABILITY OF AMORPHOUS SOLID DISPERSIONS**

Dr. Rodney Ketner, Bend Research, a division of Capsugel, Bend, OR, USA

## **IN SILICO THERMODYNAMIC AND KINETIC STABILITY OF AMORPHOUS SOLID DISPERSIONS**

Dr. Jeffrey Tan, Eli Lilly, Indianapolis, IN, USA

## **ANALYSIS OF UNSTABLE DEGRADATION IMPURITIES AND THEIR QUANTIFICATION WITHOUT ISOLATION USING MULTIPLE LINEAR REGRESSION**

Dr. John Campbell, GlaxoSmithKline, Philadelphia, PA, USA

## **DRUG DEGRADATION MECHANISMS**

Dr. Steve Baertschi, Baertschi Consulting, Indianapolis, IN, USA

## **STRESS TESTING IN SOLID STATE: TOWARDS A REALISTIC DEGRADATION PROFILE**

Dr. Peter Persich, Janssen Pharmaceuticals (J&J), Beerse, Belgium

## **UNDERSTANDING IMPORTANCE OF WATER SORPTION ISOTHERM SHAPE, HYSTERESIS, AND MODELS ON PHARMACEUTICAL MATERIALS**

Dr. Daniel Burnett, Surface Measurements Systems, Allentown, PA, USA

## **CASE STUDIES IN DRUG PACKAGING: SUPPORTING STABILITY BY ADDRESSING SPECIFIC PRESERVATION CHALLENGES**

Mr. Valère Logel, Clariant Healthcare Packaging, Paris, France